M&A Deal Summary |
|
|---|---|
| Date | 2024-04-05 |
| Target | ShockWave Medical |
| Sector | Life Science |
| Buyer(s) | Johnson & Johnson |
| Deal Type | Add-on Acquisition |
| Deal Value | 13.1B USD |
| Advisor(s) | Perella Weinberg Partners (Financial) Fenwick & West (Legal) |
SEARCH BY
Try For Free 7-Day Free Trial
| Category | Company |
|---|---|
| Founded | 1886 |
| Sector | Consumer Products |
| Employees | 132,000 |
| Revenue | 85.2B USD (2023) |
Johnson & Johnson is a global healthcare conglomerate that operates across three primary sectors: Pharmaceuticals, Medical Devices, and Consumer Health. In Pharmaceuticals, it develops treatments for a variety of conditions, including immunology, oncology, and infectious diseases. The Medical Devices segment offers a range of equipment and devices for healthcare professionals, encompassing orthopedics, surgery, and cardiovascular care. Its Consumer Health division markets a wide array of products, spanning baby care, oral care, skin care, over-the-counter drugs, and women's health, with popular brands such as Band-Aid, Tylenol, and Neutrogena under its umbrella. Johnson & Johnson was formed in 1886 and is based in New Brunswick, New Jersey.
| DEAL STATS | # |
|---|---|
| Overall | 43 of 45 |
| Sector (Life Science) | 17 of 18 |
| Type (Add-on Acquisition) | 34 of 36 |
| State (California) | 15 of 16 |
| Country (United States) | 36 of 37 |
| Year (2024) | 2 of 4 |
| Size (of disclosed) | 5 of 29 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2024-01-08 |
Ambrx
San Diego, California, United States Ambrx is a clinical-stage biopharmaceutical company with a proprietary synthetic biology technology platform to design and develop next-generation antibody-drug conjugates (ADCs). The company is advancing a focused portfolio of clinical and preclinical programs designed to optimize efficacy and safety of its candidate therapeutics in multiple cancer indications, including ARX517, its proprietary ADC targeting PSMA for metastatic castration-resistant prostate cancer (mCRPC); ARX788, its proprietary ADC targeting human epidermal growth factor receptor 2 (HER2) for metastatic HER2+ breast cancer; and ARX305, its proprietary ADC targeting CD-70 for renal cell carcinoma. Ambrx was founded in 2003 and is based in San Diego, California. |
Buy | $2.0B |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2024-05-16 |
Proteologix
California, United States Proteologix is a privately held biotechnology company focused on bispecific antibodies for immune-mediated diseases. The company's portfolio includes PX128, a bispecific antibody targeting IL-13 plus TSLP, which is ready to enter phase 1 development for moderate to severe atopic dermatitis (AD) and moderate to severe asthma, and PX130, a bispecific antibody targeting IL-13 plus IL-22, which is in preclinical development for moderate to severe AD. Proteologix is based in California. |
Buy | $850M |
